Showing results (141-150 of 255) with videos related to

Sort By:
Pageof 26
BMJ Open|April 8, 2022
Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trialRoberta Maroni, Jessica Barnes, Judith Offman, et al.
BMC Cancer|September 1, 2022
ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trialElizabeth Smyth, Kelly Cozens, Daniel Griffiths, et al.
Gastrointestinal Endoscopy|January 30, 2014
Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillanceYean Cheant Lim, Massimiliano di Pietro, Maria O'Donovan, et al.
The American Journal of Gastroenterology|August 16, 2017
Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center StudyDavid A Katzka, Thomas C Smyrk, Jeffrey A Alexander, et al.
The American Journal of Gastroenterology|December 20, 2017
Corrigendum: Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center StudyDavid A Katzka, Thomas C Smyrk, Jeffrey A Alexander, et al.
BMC Gastroenterology|January 10, 2023
Predictors of the experience of a Cytosponge test: analysis of patient survey data from the BEST3 trialBhagabati Ghimire, Rebecca Landy, Roberta Maroni, et al.
The Journal of Pathology|June 27, 2012
Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesisAnna L Paterson, Maria O'Donovan, Elena Provenzano, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2015
CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapyJudith Honing, Kirill V Pavlov, Véronique E M Mul, et al.
Histopathology|March 11, 2022
The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasiaWladyslaw Januszewicz, Nastazja D Pilonis, Tarek Sawas, et al.
Frontiers in Immunology|June 6, 2022
Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering ApproachSrinand Sundaram, Eun Na Kim, Georgina M Jones, et al.
Pageof 26